Aayerah Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 40.86%
- Profit Growth 98.89%
- Ebitda 152.49%
- Net Worth -2.73%
- Total Assets 52.69%
About Aayerah Pharmaceuticals
Aayerah Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 January 2019 (Six years and one month 6 days old ). Its registered office is in Khorda, Odisha, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Akbar Khan and Halima Sadeeya serve as directors at the Company.
Company Details
- Location
Khorda, Odisha, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U85100OR2019PTC030264
- Company No.
030264
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jan 2019
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Aayerah Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akbar Khan  | Director | 11-Oct-2021 | Current |
| Halima Sadeeya | Director | 15-Jan-2019 | Current |
Financial Performance of Aayerah Pharmaceuticals.
Aayerah Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 40.86% increase. The company also saw a substantial improvement in profitability, with a 98.89% increase in profit. The company's net worth dipped by a decrease of 2.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aayerah Pharmaceuticals?
Unlock access to Aayerah Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Aalarik Commodity Private LimitedHalima Sadeeya is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aayerah Pharmaceuticals?
Unlock and access historical data on people associated with Aayerah Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aayerah Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aayerah Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
